Gene therapy expands to second eye in rare vision loss trial
NCT ID NCT07586306
First seen May 17, 2026 · Last updated May 21, 2026 · Updated 1 time
Summary
This study tests a gene therapy called VGR-R01 in the second eye of 15 people with Bietti's crystalline dystrophy, a rare inherited eye disease that causes vision loss. Participants already received the therapy in one eye in a previous study. The main goal is to check safety, and researchers will also measure changes in vision and mobility.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanghai General Hospital (Shanghai First People's Hospital)
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.